No Data
No Data
Anges --- Stanford Medical School SLDDDRS Funding Cooperation
Anges <4563> announced financial cooperation for Stanford University Medical School SLDDDRS on the 15th. The company will strengthen the relationship with the Leland Stanford Stanford Junior University Board of Trustees and Stanford University Medical School's Stanford Laboratory for Drug, Device Development and Regulatory Sciences on 2024/5/15 to strengthen the relationship with Stanford University Medical School
Digital Plus, Genext, etc.
<3133>Kaiho Co., Ltd. Yamada Toru Stock Ownership Ratio 12.99% → 14.18% Reporting Obligation Date 2024/04/26 <3237>Intrans Co., Ltd. Intrans LLC Inbound Investment Stock Ownership Ratio 43.50% → 31.27% Reporting Obligation Date 2024/05/08 <3491>GA Technology Co., Ltd. Ryu Higuchi Stock Holding Ratio 43.17% → 42.35% Report
AnGes: Confirmation
AnGes: Quarterly Report - 26th Quarter 1 (2024/01/01 - 2024/03/31)
MonoAI, Hope, etc. [Emerging Markets Press Release]
<3727>APLIX earnings forecast revisions, current fiscal year business profit forecast 219 million yen ← 264 million yen <4262>acquisition of shares in Doors, which handles the operation of the Nifty Life exterior wall painting specialty site “Exterior Wall Painting Window,” and making it a subsidiary <4563>Anges 1st Unsecured Convertible Bonds Type Stock Acquisition Rights Corporate Bonds (with conversion price correction clauses) number of shares issued since the 13th, 736,614 shares <4579>LaQuoria Drug Discovery Exterior Wall Remodeling Support Agreement Businesses Consolidated subsidiary that handles it
Anges -- 1Q significant increase in sales, and a lump-sum contract for non-exclusive use rights of OMNI nuclease was recorded as research and development business income
Anges <4563> announced consolidated financial results for the 1st quarter (24/1/03) of the fiscal year ending 2024/12 on the 10th. Sales increased 584.0% from the same period last year to 113 million yen, operating loss was 2,476 billion yen (loss of 3,036 billion yen in the same period last year), ordinary loss was 1,527 billion yen (loss of 2,897 billion yen), and quarterly net loss attributable to parent company shareholders was 1,824 billion yen (loss of 2,911 billion yen). Business revenue for the first quarter increased significantly compared to the same period last year.
No Data